PIM
OVID icon

Platinum Investment Management’s Ovid Therapeutics OVID Stock Holding History

Platinum Investment Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-766,901
Closed -$2.46M – 146
2021
Q4 		$2.46M Hold
766,901
– – 0.07% 90
2021
Q3 		$2.58M Buy
766,901
+370,031
+93% +$1.35M 0.07% 88
2021
Q2 		$1.55M Hold
396,870
– – 0.04% 105
2021
Q1 		$1.59M Hold
396,870
– – 0.04% 101
2020
Q4 		$917K Buy
396,870
+163,457
+70% +$762K 0.02% 114
2020
Q3 		$1.34M Sell
233,413
-68,176
-23% -$456K 0.03% 97
2020
Q2 		$2.22M Sell
301,589
-81,346
-21% -$380K 0.05% 79
2020
Q1 		$1.14M Buy
382,935
+76,789
+25% +$259K 0.03% 96
2019
Q4 		$1.27M Buy
306,146
+176,546
+136% +$557K 0.03% 79
2019
Q3 		$420K Buy
+129,600
New +$295K 0.01% 94

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Platinum Investment Management's OVID Position: Q1 2022 in Review

Platinum Investment Management sold out of Ovid Therapeutics (OVID) in Q1 2022, closing a stake of 766,901 shares — an estimated $2.46M sold.

Platinum Investment Management first reported a position in OVID in Q3 2019 and held it in 10 quarters. The position peaked at $2.58M in Q3 2021. 62 funds tracked by Wall St. Rank hold OVID as of Q1 2022.

  • Platinum Investment Management reported no remaining Ovid Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Platinum Investment Management sold 766,901 Ovid Therapeutics shares in Q1 2022, an estimated $2.46M.
  • Platinum Investment Management first reported a position in Ovid Therapeutics in Q3 2019 and held it in 10 quarters.
  • Platinum Investment Management's Ovid Therapeutics position peaked at $2.58M in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2022.

Based on Platinum Investment Management's 13F filing for Q1 2022, filed 13 May 2022.